關于勃林格殷格翰<\/b><\/p> \n
勃林格殷格翰是全球領先的生物制藥企業，布局人用藥品、動物保健兩大業務領域。公司研發投入位居行業前列，致力于研究突破性療法，解決巨大未滿足的醫療需求，從而幫助改善或延長生命。自1885年成立以來，勃林格殷格翰一直是獨立的家族企業，始終著眼長遠發展，將可持續發展理念貫穿全價值鏈。公司在全球有超過5.35萬名員工，服務逾130個市場，致力于打造一個更健康、更可持續、更公平的未來。更多詳情，請訪問：www.boehringer-ingelheim.com<\/a><\/p> \n 關于<\/b>OSE IMMUNOTHERAPEUTICS<\/b><\/p> \n OSE Immunotherapeutics 是一家生物技術公司，致力于開發免疫腫瘤 (IO) 和免疫炎癥 (I&I) 領域的同類首創資產。<\/p> \n 公司當前均衡的同類首創臨床管線包括：<\/p> \n OSE Immunotherapeutics 期望進一步發掘其三個專有藥物發現平臺的重大價值，這些平臺是公司實現提供下一代同類首創免疫療法宏偉目標的核心：<\/p> \n Forward-looking statements These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on May 2, 2023<\/span>, including the annual financial report for the fiscal year 2022, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.<\/p> \n <\/p>"];
$("#dvExtra").html(content_array[0]);})(); \n
\n
傳遞<\/s>遞送。BiCKI®是一個雙功能融合蛋白平臺，建立在抗PD1的關鍵骨架成分上，與新的免疫治療靶點相結合，以提高抗腫瘤功效。<\/li> \n
<\/b>This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.<\/p> \n